Business
OncoQuest Announces a U.S.$50 Million Investment by KOSDAQ listed Dual Industrial Co. Ltd.
OncoQuest Announces a U.S.$50 Million Investment by KOSDAQ listed Dual Industrial Co. Ltd....
About this update from Quest Pharmatech Inc.
[{"type":"text","content":"\n\n\n\nOncoQuest Announces a U.S.$50 Million Investment by KOSDAQ listed Dual Industrial Co. Ltd.\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nEDMONTON, March 13, 2020\n\n\n\nConsideration is U.S.$10 million in Cash and U.S.$40 million in a Convertible Bond \n EDMONTON, March 13, 2020 /CNW/ - OncoQuest Inc., (\"OncoQuest\") a privately held, cancer immunotherapy company, a subsidiary of Quest PharmaTech Inc. (TSXV: QPT) today announced that it has closed a private placement totaling U.S.$50 million at U.S.$20.00 per share. The investor, Dual Industrial Co. Ltd. (Dual), is a publicly traded Korean company on the KOSDAQ.  OncoQuest issued 2.5 million common shares in exchange for U.S.$10 million in cash and U.S.$40 million in a bond convertible into Dual shares. The proceeds will be primarily used for expenses related to the oregovomab Phase III clinical trial for the treatment of frontline ovarian cancer.\n\"We believe the investment by Dual is a validation of OncoQuest's technology and creates shareholder value to Quest, which owns 45% of OncoQuest, as well as to other shareholders of OncoQuest,\" commented Dr. Madiyalakan, CEO of OncoQuest and Quest PharmaTech.\nAbout OncoQuest \nOncoQuest is a subsidiary of Quest PharmaTech Inc. (TSXV: QPT) (\"Quest\") and is a private biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer. OncoQuest's technology platform includes a portfolio of tumor antigen specific monoclonal immunoglobulins including CA-125, MUC1, PSA and Her2/neu.  The company is exploring the therapeutic potential of these antibodies in combination with other immune modulating drugs or drug combinations to enhance tumor specific immunity and clinical outcomes. To learn more, visit www.oncoquestinc.com . \nAbout Dual Industrial Co. Ltd. Dual Industrial Co., Ltd. (\"Dual Industrial\") is a publicly traded Korean company listed on the [KOSDAQ 078590]. Dual Industrial develops and manufactures Automobile IN/EX materials parts as the first primary v...